Related Experiment Video
Updated: Jun 16, 2025
A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis
Published on: June 2, 2015
Study of Use of Dabigatran in Cerebral Venous Sinus Thrombosis
Satish Nirhale1, Shalesh Rohatgi1, Prajwal Rao1
1Neurology, Dr. D Y Patil Medical College, Hospital and Research Centre, Dr. D Y Patil Vidyapeeth (Deemed to be University), Pune, IND.
Insights
New research suggests dabigatran is a safe and effective treatment for cerebral venous sinus thrombosis (CVST). This study found all patients treated with dabigatran achieved re-canalization with no major complications, indicating its potential as a viable therapy for CVST.
Area of Science:
- Neurology
- Hematology
- Radiology
Background:
- Cerebral venous sinus thrombosis (CVST) presents diverse symptoms, complicating diagnosis and treatment.
- Current standard anticoagulation therapy (heparin, warfarin) has remained unchanged for decades.
- Direct oral anticoagulants (NOACs) offer potential advantages over traditional therapies.
Purpose of the Study:
- To investigate the efficacy and safety of dabigatran for treating cerebral venous sinus thrombosis (CVST).
- To evaluate dabigatran's impact on re-canalization and complication rates in CVST patients.
Main Methods:
- Prospective observational study involving 30 patients with diagnosed CVST.
- Patients received a standard dose of dabigatran etexilate (150 mg twice daily).
- Magnetic resonance imaging (MRI) with magnetic resonance venography (MRV) was used for diagnosis.
Main Results:
- Headache was the most frequent presenting symptom among participants.
- All patients treated with dabigatran achieved successful re-canalization of cerebral venous sinuses.
- No major complications were reported in the dabigatran-treated group.
Conclusions:
- Dabigatran demonstrates promising efficacy and safety as a treatment for cerebral venous sinus thrombosis.
- Further large-scale, multi-center studies are warranted to confirm these findings.
- Dabigatran may represent a valuable alternative treatment option for CVST.
Abstract:
Cerebral venous sinus thrombosis (CVST) is a challenging condition to diagnose and treat due to its diverse range of clinical presentations. The incidence of CVST is increasing, and although diagnostic techniques have improved, the mainstay of treatment is heparin followed by vitamin K antagonist (VKA), warfarin has remained largely unchanged for the past three decades. However, new direct oral anticoagulants (NOACs) like dabigatran have been developed to address the limitations of VKA therapy. Magnetic resonance imaging (MRI) with magnetic resonance venography (MRV) is the current preferred diagnostic method for CVST due to its exceptional sensitivity and specificity. This prospective observational study was set out to investigate the efficacy and safety of dabigatran in treating cerebral venous sinus thrombosis. The study included 30 patients who reported regular intake of 150 mg dabigatran etexilate twice a day. Among the participants, headache was the most commonly reported symptom. The study found that patients treated with dabigatran experienced favorable outcomes, with all patients achieving re-canalization and reporting no major complications. These promising results suggest that dabigatran could be an effective treatment option for CVST cases. However, the study emphasizes the need for larger, multi-center studies to further validate these findings and improve the overall understanding of the condition and its treatment options.
